View details of this raise on Seedstage

Shreveport, LA

Developing a sustained-release injection for osteoarthritis pain relief and potential disease modification.

• Innovative Treatment: CAL-05CR offers sustained pain relief and potential disease-modifying benefits for osteoarthritis.
• Proprietary Technology: Utilizes a PLGA microsphere system for extended treatment intervals.
• Positive Clinical Data: Phase 1 trials show significant pain reduction using calcium ion channel blockers.
• Scalable Manufacturing: Plans for manufacturing with Lonza to ensure reliable production.
• Regulatory Pathway: Leverages FDA’s 505(b)(2) pathway to potentially reduce development timelines.

Calosyn Pharma is developing CAL-05CR, a sustained-release verapamil injection aimed at providing both pain relief and potential disease-modifying benefits for osteoarthritis patients. The product utilizes a proprietary PLGA microsphere system to extend treatment intervals up to six months. With positive Phase 1 data on calcium ion channel blockers and a strong new IP portfolio, Calosyn is planning scalable manufacturing with Lonza. The company is positioned for growth in a market estimated at nearly $10 billion.

Osteoarthritis affects over 32.5 million adults in the U.S., presenting a treatment gap between short-term symptom relief and long-term joint health. Standard injections require frequent administration and generally offer no disease-modifying effects. Calosyn’s CAL-05CR uses verapamil, delivered via PLGA microspheres, for sustained intra-articular release projected for up to six months. Preclinical studies show potential cartilage preservation, and early clinical trials demonstrate significant pain reduction. The treatment is designed to be easy for physicians to administer, leveraging the FDA’s 505(b)(2) regulatory pathway to potentially reduce development timelines and costs.

Company Info

Calosyn Pharma is developing a sustained-release injection for osteoarthritis, aiming to provide long-lasting pain relief and potential disease-modifying benefits.

Calosyn Pharma is focused on developing CAL-05CR, a sustained-release injectable treatment for osteoarthritis. This investigational therapy utilizes verapamil, a calcium channel blocker, embedded in PLGA microspheres to provide long-lasting pain relief and potential disease-modifying effects. The treatment aims to address the limitations of current osteoarthritis therapies by offering extended relief with fewer injections, targeting both pain and the underlying pathophysiology of the disease.

The company has completed Phase 1 trials demonstrating significant pain reduction and is planning further development, including pre-IND manufacturing and FDA discussions. Calosyn’s approach leverages a proprietary drug delivery system designed to release therapeutic concentrations over a projected six-month period, potentially improving patient outcomes and quality of life. With a strong IP portfolio and plans for scalable manufacturing, Calosyn is positioned to make a significant impact in the osteoarthritis treatment market.